AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sanofi Acquires Vigil Neuroscience for $470 Million, Strengthens Neurology Pipeline
ByAinvest
Wednesday, Aug 6, 2025 1:02 am ET1min read
Sanofi has completed the acquisition of Vigil Neuroscience, a neurology-focused biotech, for $470m. The acquisition includes VG-3927, a novel oral TREM2 agonist being evaluated in a phase 2 clinical study for Alzheimer's disease. Sanofi's financial guidance for 2025 is not impacted by the acquisition.
Sanofi has finalized the acquisition of Vigil Neuroscience, Inc., a clinical-stage biotechnology company focused on developing treatments for rare and common neurodegenerative diseases. The acquisition, valued at approximately $470 million, includes the rights to VG-3927, a novel oral TREM2 agonist being evaluated in a phase 2 clinical study for Alzheimer's disease. The acquisition does not impact Sanofi's financial guidance for 2025.The deal involves Sanofi acquiring all outstanding shares of Vigil Neuroscience for $8 per share, totaling approximately $470 million on a fully diluted basis. Additionally, shareholders of Vigil Neuroscience will receive a deferred cash payment of $2 per share upon the first commercial sale of VG-3927. The acquisition also includes the rights to VG-3927, an orally available small molecule TREM2 agonist being evaluated in a phase 1 clinical trial for Alzheimer's disease in genetically defined subpopulations.
Sanofi's acquisition of Vigil Neuroscience is expected to strengthen its pipeline in neurology, particularly in the area of microglial dysfunction, a key factor in neurodegenerative diseases such as Alzheimer's. The company's lead candidate, VGL101, is a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2, currently in a phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Sanofi's acquisition strategy reflects its commitment to innovation in the field of neurology. The company's acquisition of Vigil Neuroscience aligns with its mission to pursue scientific breakthroughs that improve the lives of millions of people worldwide.
References:
[1] https://www.globenewswire.com/news-release/2025/08/06/3128014/0/fr/Communiqu%C3%A9-de-presse-Sanofi-finalise-l-acquisition-de-Vigil-Neuroscience-Inc.html
[2] https://finance.yahoo.com/quote/VIGL/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet